FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005473445> ?p ?o ?g. }

• W3005473445 endingPage "1112" @default.
• W3005473445 startingPage "1105" @default.
• W3005473445 abstract "Purpose Aggressive posterior retinopathy of prematurity (AP-ROP) is a vision-threatening disease with a significant rate of progression to retinal detachment. The purpose of this study was to characterize AP-ROP quantitatively by demographics, rate of disease progression, and a deep learning-based vascular severity score. Design Retrospective analysis. Participants The Imaging and Informatics in ROP cohort from 8 North American centers, consisting of 947 patients and 5945 clinical eye examinations with fundus images, was used. Pretreatment eyes were categorized by disease severity: none, mild, type 2 or pre-plus, treatment-requiring (TR) without AP-ROP, TR with AP-ROP. Analyses compared TR with AP-ROP and TR without AP-ROP to investigate differences between AP-ROP and other TR disease. Methods A reference standard diagnosis was generated for each eye examination using previously published methods combining 3 independent image-based gradings and 1 ophthalmoscopic grading. All fundus images were analyzed using a previously published deep learning system and were assigned a score from 1 through 9. Main Outcome Measures Birth weight, gestational age, postmenstrual age, and vascular severity score. Results Infants who demonstrated AP-ROP were more premature by birth weight (617 g vs. 679 g; P = 0.01) and gestational age (24.3 weeks vs. 25.0 weeks; P < 0.01) and reached peak severity at an earlier postmenstrual age (34.7 weeks vs. 36.9 weeks; P < 0.001) compared with infants with TR without AP-ROP. The mean vascular severity score was greatest in TR with AP-ROP infants compared with TR without AP-ROP infants (8.79 vs. 7.19; P < 0.001). Analyzing the severity score over time, the rate of progression was fastest in infants with AP-ROP (P < 0.002 at 30–32 weeks). Conclusions Premature infants in North America with AP-ROP are born younger and demonstrate disease earlier than infants with less severe ROP. Disease severity is quantifiable with a deep learning-based score, which correlates with clinically identified categories of disease, including AP-ROP. The rate of progression to peak disease is greatest in eyes that demonstrate AP-ROP compared with other treatment-requiring eyes. Analysis of quantitative characteristics of AP-ROP may help improve diagnosis and treatment of an aggressive, vision-threatening form of ROP. Aggressive posterior retinopathy of prematurity (AP-ROP) is a vision-threatening disease with a significant rate of progression to retinal detachment. The purpose of this study was to characterize AP-ROP quantitatively by demographics, rate of disease progression, and a deep learning-based vascular severity score. Retrospective analysis. The Imaging and Informatics in ROP cohort from 8 North American centers, consisting of 947 patients and 5945 clinical eye examinations with fundus images, was used. Pretreatment eyes were categorized by disease severity: none, mild, type 2 or pre-plus, treatment-requiring (TR) without AP-ROP, TR with AP-ROP. Analyses compared TR with AP-ROP and TR without AP-ROP to investigate differences between AP-ROP and other TR disease. A reference standard diagnosis was generated for each eye examination using previously published methods combining 3 independent image-based gradings and 1 ophthalmoscopic grading. All fundus images were analyzed using a previously published deep learning system and were assigned a score from 1 through 9. Birth weight, gestational age, postmenstrual age, and vascular severity score. Infants who demonstrated AP-ROP were more premature by birth weight (617 g vs. 679 g; P = 0.01) and gestational age (24.3 weeks vs. 25.0 weeks; P < 0.01) and reached peak severity at an earlier postmenstrual age (34.7 weeks vs. 36.9 weeks; P < 0.001) compared with infants with TR without AP-ROP. The mean vascular severity score was greatest in TR with AP-ROP infants compared with TR without AP-ROP infants (8.79 vs. 7.19; P < 0.001). Analyzing the severity score over time, the rate of progression was fastest in infants with AP-ROP (P < 0.002 at 30–32 weeks). Premature infants in North America with AP-ROP are born younger and demonstrate disease earlier than infants with less severe ROP. Disease severity is quantifiable with a deep learning-based score, which correlates with clinically identified categories of disease, including AP-ROP. The rate of progression to peak disease is greatest in eyes that demonstrate AP-ROP compared with other treatment-requiring eyes. Analysis of quantitative characteristics of AP-ROP may help improve diagnosis and treatment of an aggressive, vision-threatening form of ROP." @default.
• W3005473445 created "2020-02-14" @default.
• W3005473445 creator A5004322198 @default.
• W3005473445 creator A5009286480 @default.
• W3005473445 creator A5013498181 @default.
• W3005473445 creator A5033034428 @default.
• W3005473445 creator A5037620955 @default.
• W3005473445 creator A5039535916 @default.
• W3005473445 creator A5049608028 @default.
• W3005473445 creator A5054028651 @default.
• W3005473445 creator A5057746028 @default.
• W3005473445 creator A5073997396 @default.
• W3005473445 creator A5087030070 @default.
• W3005473445 date "2020-08-01" @default.
• W3005473445 modified "2023-10-18" @default.
• W3005473445 title "Aggressive Posterior Retinopathy of Prematurity" @default.
• W3005473445 cites W1974052518 @default.
• W3005473445 cites W1990555365 @default.
• W3005473445 cites W2007763447 @default.
• W3005473445 cites W2040447587 @default.
• W3005473445 cites W2069082019 @default.
• W3005473445 cites W2134440316 @default.
• W3005473445 cites W2153200400 @default.
• W3005473445 cites W2169111263 @default.
• W3005473445 cites W2338036999 @default.
• W3005473445 cites W2394656367 @default.
• W3005473445 cites W2402115649 @default.
• W3005473445 cites W2507467374 @default.
• W3005473445 cites W2561863836 @default.
• W3005473445 cites W2590477903 @default.
• W3005473445 cites W2603127898 @default.
• W3005473445 cites W2615077572 @default.
• W3005473445 cites W2622241366 @default.
• W3005473445 cites W2741822194 @default.
• W3005473445 cites W2800012666 @default.
• W3005473445 cites W2810455825 @default.
• W3005473445 cites W2901661131 @default.
• W3005473445 cites W2903660357 @default.
• W3005473445 cites W2937267606 @default.
• W3005473445 cites W2953404818 @default.
• W3005473445 cites W2954643276 @default.
• W3005473445 cites W2987163607 @default.
• W3005473445 cites W3148465273 @default.
• W3005473445 cites W948713399 @default.
• W3005473445 doi "https://doi.org/10.1016/j.ophtha.2020.01.052" @default.
• W3005473445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7384953" @default.
• W3005473445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32197913" @default.
• W3005473445 hasPublicationYear "2020" @default.
• W3005473445 type Work @default.
• W3005473445 sameAs 3005473445 @default.
• W3005473445 citedByCount "26" @default.
• W3005473445 countsByYear W30054734452020 @default.
• W3005473445 countsByYear W30054734452021 @default.
• W3005473445 countsByYear W30054734452022 @default.
• W3005473445 countsByYear W30054734452023 @default.
• W3005473445 crossrefType "journal-article" @default.
• W3005473445 hasAuthorship W3005473445A5004322198 @default.
• W3005473445 hasAuthorship W3005473445A5009286480 @default.
• W3005473445 hasAuthorship W3005473445A5013498181 @default.
• W3005473445 hasAuthorship W3005473445A5033034428 @default.
• W3005473445 hasAuthorship W3005473445A5037620955 @default.
• W3005473445 hasAuthorship W3005473445A5039535916 @default.
• W3005473445 hasAuthorship W3005473445A5049608028 @default.
• W3005473445 hasAuthorship W3005473445A5054028651 @default.
• W3005473445 hasAuthorship W3005473445A5057746028 @default.
• W3005473445 hasAuthorship W3005473445A5073997396 @default.
• W3005473445 hasAuthorship W3005473445A5087030070 @default.
• W3005473445 hasBestOaLocation W30054734452 @default.
• W3005473445 hasConcept C118487528 @default.
• W3005473445 hasConcept C126322002 @default.
• W3005473445 hasConcept C167135981 @default.
• W3005473445 hasConcept C187212893 @default.
• W3005473445 hasConcept C2776391266 @default.
• W3005473445 hasConcept C2778376644 @default.
• W3005473445 hasConcept C2779234561 @default.
• W3005473445 hasConcept C2779918416 @default.
• W3005473445 hasConcept C54355233 @default.
• W3005473445 hasConcept C66322754 @default.
• W3005473445 hasConcept C71924100 @default.
• W3005473445 hasConcept C72563966 @default.
• W3005473445 hasConcept C86803240 @default.
• W3005473445 hasConceptScore W3005473445C118487528 @default.
• W3005473445 hasConceptScore W3005473445C126322002 @default.
• W3005473445 hasConceptScore W3005473445C167135981 @default.
• W3005473445 hasConceptScore W3005473445C187212893 @default.
• W3005473445 hasConceptScore W3005473445C2776391266 @default.
• W3005473445 hasConceptScore W3005473445C2778376644 @default.
• W3005473445 hasConceptScore W3005473445C2779234561 @default.
• W3005473445 hasConceptScore W3005473445C2779918416 @default.
• W3005473445 hasConceptScore W3005473445C54355233 @default.
• W3005473445 hasConceptScore W3005473445C66322754 @default.
• W3005473445 hasConceptScore W3005473445C71924100 @default.
• W3005473445 hasConceptScore W3005473445C72563966 @default.
• W3005473445 hasConceptScore W3005473445C86803240 @default.
• W3005473445 hasFunder F4320306076 @default.
• W3005473445 hasFunder F4320332161 @default.
• W3005473445 hasIssue "8" @default.
• W3005473445 hasLocation W30054734451 @default.

• next